While studies have focused on mineral metabolism components such as FGF23 and α-klotho, additional prospective research is needed to fully understand the mechanisms through which FGF23 and α-klotho contribute to atherosclerosis in T2DM patients and to validate the role of FGF23/α-klotho ratio as a novel marker. The gene discussed is FGF23; the disease is atherosclerosis.